A real-life observational study in severe eosinophilic asthma adult participant treated with benralizumab in Italy - ATHENA

Inclusion Criteria

• Inclusion Criteria:
• - Adults (≥ 18 years old) diagnosed with severe uncontrolled eosinophilic asthma.
• - Benralizumab has been prescribed according to the approved label and local reimbursement criteria
• - Provision of signed Informed Consent Form (ICF) prior to any study-related activities
• - Benralizumab has been initiated within 7 days prior to study enrollment or is planned to be initiated within 7 days after enrollment (in the latter case, provided that the decision to prescribe benralizumab is made prior to the decision to enroll the patient in the study).
• Exclusion Criteria:
• - Benralizumab treatment within the 12 months prior to study enrollment and up to 8 days before enrollment
• - Previous participation (in the 12 months before enrollment), current participation or plan to participate within the follow up period to any other clinical trial.
• - Contraindication to benralizumab as per current Summary of Product Characteristics (SmPC).
• - Pregnant or lactating women.
• - patients with any clinical condition that may interfere with the subject's ability to cooperate and comply with the study procedures based on the Investigator's judgement.
• - Previous or concomitant use of omalizumab, reslizumab, dupilumab, tezepelumab or mepolizumab without washout period as per clinical practice